PL3215147T3 - Związki norketaminy osłabiającej działanie układu nerwowego i sposoby - Google Patents
Związki norketaminy osłabiającej działanie układu nerwowego i sposobyInfo
- Publication number
- PL3215147T3 PL3215147T3 PL15856205.8T PL15856205T PL3215147T3 PL 3215147 T3 PL3215147 T3 PL 3215147T3 PL 15856205 T PL15856205 T PL 15856205T PL 3215147 T3 PL3215147 T3 PL 3215147T3
- Authority
- PL
- Poland
- Prior art keywords
- neuro
- methods
- attenuating norketamine
- compounds
- norketamine compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074645P | 2014-11-04 | 2014-11-04 | |
| PCT/US2015/059113 WO2016073653A1 (en) | 2014-11-04 | 2015-11-04 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3215147T3 true PL3215147T3 (pl) | 2024-06-24 |
Family
ID=55909773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15856205.8T PL3215147T3 (pl) | 2014-11-04 | 2015-11-04 | Związki norketaminy osłabiającej działanie układu nerwowego i sposoby |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10252982B2 (pl) |
| EP (2) | EP4393487A3 (pl) |
| JP (2) | JP6882180B2 (pl) |
| KR (1) | KR102604397B1 (pl) |
| CN (2) | CN115521217A (pl) |
| AU (1) | AU2015343083B2 (pl) |
| CA (1) | CA2966737A1 (pl) |
| DK (1) | DK3215147T3 (pl) |
| ES (1) | ES2977383T3 (pl) |
| FI (1) | FI3215147T3 (pl) |
| HU (1) | HUE066468T2 (pl) |
| LT (1) | LT3215147T (pl) |
| PL (1) | PL3215147T3 (pl) |
| PT (1) | PT3215147T (pl) |
| RS (1) | RS65411B1 (pl) |
| RU (1) | RU2771275C2 (pl) |
| SI (1) | SI3215147T1 (pl) |
| WO (1) | WO2016073653A1 (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| PL3287124T3 (pl) | 2014-04-17 | 2023-02-20 | Ketabon Gmbh | Doustna postać dawkowania ketaminy |
| DK3215147T3 (da) * | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| US11426366B2 (en) * | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| US20190256487A1 (en) * | 2016-09-16 | 2019-08-22 | BioPharmaWorks, LLC | Hydroxynorketamine prodrugs |
| AU2017351437B2 (en) * | 2016-10-27 | 2022-01-27 | National University Corporation Chiba University | Application of (S)-norketamine and salt thereof as pharmaceutical |
| CA3059775A1 (en) | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| CA3071491A1 (en) | 2017-07-31 | 2019-02-07 | Small Pharma Ltd | Crystalline forms of hydroxynorketamine |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| CN111630026A (zh) * | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| WO2022064387A1 (en) * | 2020-09-24 | 2022-03-31 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| KR20220002905A (ko) * | 2019-03-25 | 2022-01-07 | 더글라스 파머수티클스 리미티드 | 서방형 약학 제제 |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CA3148992A1 (en) * | 2019-08-06 | 2021-02-11 | The Regents Of The University Of California | Scaleable preparation of polyketides |
| EP4041209A4 (en) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー. | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| WO2021137148A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| MX2022014599A (es) * | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| US20240207338A1 (en) * | 2021-04-30 | 2024-06-27 | Progressive Therapeutics Inc | Ketamine and cannabis for the treatment of emotional disorders |
| CN116730853A (zh) * | 2022-03-04 | 2023-09-12 | 上海致根医药科技有限公司 | 新型氨基酮类化合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| JP2006510618A (ja) * | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス,インコーポレーテッド | ノルケタミンおよびケタミン/ノルケタミンプロドラッグの鎮痛的使用 |
| US20100076087A1 (en) * | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| BRPI0809843A2 (pt) * | 2007-04-26 | 2014-09-23 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| WO2009131794A1 (en) * | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| CA2922507C (en) | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| DK3215147T3 (da) | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
-
2015
- 2015-11-04 DK DK15856205.8T patent/DK3215147T3/da active
- 2015-11-04 WO PCT/US2015/059113 patent/WO2016073653A1/en not_active Ceased
- 2015-11-04 EP EP24159685.7A patent/EP4393487A3/en active Pending
- 2015-11-04 RU RU2017119222A patent/RU2771275C2/ru active
- 2015-11-04 CA CA2966737A patent/CA2966737A1/en active Pending
- 2015-11-04 KR KR1020177015310A patent/KR102604397B1/ko active Active
- 2015-11-04 PL PL15856205.8T patent/PL3215147T3/pl unknown
- 2015-11-04 US US15/524,224 patent/US10252982B2/en active Active
- 2015-11-04 SI SI201532004T patent/SI3215147T1/sl unknown
- 2015-11-04 PT PT158562058T patent/PT3215147T/pt unknown
- 2015-11-04 JP JP2017543308A patent/JP6882180B2/ja active Active
- 2015-11-04 AU AU2015343083A patent/AU2015343083B2/en active Active
- 2015-11-04 LT LTEPPCT/US2015/059113T patent/LT3215147T/lt unknown
- 2015-11-04 CN CN202211196697.5A patent/CN115521217A/zh active Pending
- 2015-11-04 CN CN201580072316.4A patent/CN107106529A/zh active Pending
- 2015-11-04 HU HUE15856205A patent/HUE066468T2/hu unknown
- 2015-11-04 ES ES15856205T patent/ES2977383T3/es active Active
- 2015-11-04 FI FIEP15856205.8T patent/FI3215147T3/fi active
- 2015-11-04 RS RS20240383A patent/RS65411B1/sr unknown
- 2015-11-04 EP EP15856205.8A patent/EP3215147B1/en active Active
-
2019
- 2019-02-08 US US16/271,767 patent/US10981859B2/en active Active
-
2021
- 2021-03-09 US US17/196,986 patent/US11603348B2/en active Active
- 2021-05-06 JP JP2021078368A patent/JP2021120389A/ja active Pending
-
2022
- 2022-08-05 US US17/882,046 patent/US11613515B2/en active Active
-
2023
- 2023-02-14 US US18/168,950 patent/US12466783B2/en active Active
-
2025
- 2025-10-13 US US19/356,894 patent/US20260109663A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| PL3215147T3 (pl) | Związki norketaminy osłabiającej działanie układu nerwowego i sposoby | |
| IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| GB201413086D0 (en) | Methods | |
| SG11201704473WA (en) | New methods and uses | |
| IL251107A0 (en) | Compounds and methods | |
| GB201608779D0 (en) | Methods and compounds | |
| GB201608776D0 (en) | Methods and compounds | |
| GB201408745D0 (en) | Methods | |
| GB201421752D0 (en) | Cafetiere | |
| GB201419650D0 (en) | Modified heterocyclase | |
| GB201415250D0 (en) | Compound and method | |
| GB201408091D0 (en) | Methods and uses | |
| GB201401268D0 (en) | TrackPack | |
| GB201415685D0 (en) | Methods | |
| AU5594P (en) | Lanoregon Mandevilla sanderi | |
| AU5583P (en) | Lanminnesota Mandevilla sanderi | |
| AU5597P (en) | Lancalifornia Mandevilla sanderi | |
| AU5285P (en) | FLOMANRER Mandevilla sanderi | |
| GB201404301D0 (en) | Compounds and combinations | |
| GB201416073D0 (en) | Methods and uses | |
| GB201416086D0 (en) | Methods and uses | |
| GB201414122D0 (en) | Methods | |
| GB201407599D0 (en) | New compounds and uses | |
| GB201407596D0 (en) | New compounds and uses |